BOULDER, Colo., Oct. 23, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2013 on Monday, October 29, 2012, and will hold a conference call on Tuesday, October 30, 2012 at 9:00 a.m. eastern time to discuss these results. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Conference Call Information | |
Date: | Tuesday, October 30, 2012 |
Time: | 9:00 a.m. eastern time |
Toll-Free: | 866-383-8119 |
Toll: | 617-597-5344 |
Pass Code: | 70615778 |
Webcast & Conference Call Slides: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhome | |
A replay of the call will be available as a webcast on www.arraybiopharma.com
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted smallmolecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two whollyowned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma Inc.
